Financiado en parte por GlaxoSmithKline
Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults
Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, Krueger D, Drezner MK
The Journal of clinical endocrinology and metabolism · 118 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- GlaxoSmithKline
- Gobierno
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Gobierno
- NIAMS NIH HHS
- Subvenciones
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR027032)
Según 3 financiadores declarados.
Publicación
- Publicado
- 2011-02-03 · J Clin Endocrinol Metab · vol. 96 · número 4 · págs. 981–988
- Editorial
- Oxford University Press
- Citado
- 175 citas · más que el 99% de estudios similares · 12.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 37 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · Bone health and osteoporosis research · Parathyroid Disorders and Treatments
- Palabras clave
- vitamin D2, vitamin D3, 25-hydroxyvitamin D, vitamin D deficiency, older adults, serum calcium, urinary calcium, parathyroid hormone, bone turnover markers, vitamin D toxicity
- MeSH
- humans, osteoporosis, calcium, cholecalciferol, ergocalciferols, vitamin d, dosage forms, placebos, drug administration schedule, double-blind method, circadian rhythm, dose-response relationship, drug, aged, aged, 80 and over, female, male, bone density conservation agents
7 autores
- Neil Binkley🇺🇸 · autor de correspondenciaUniversity of Wisconsin–Madison
- Dessa Gemar🇺🇸University of Wisconsin–Madison
- Jean A. Engelke🇺🇸University of Wisconsin–Madison
- Ronald E. Gangnon🇺🇸University of Wisconsin–Madison
- Rekha Ramamurthy🇺🇸University of Wisconsin–Madison
- Diane C. Krueger🇺🇸University of Wisconsin–Madison
- M. K. Drezner🇺🇸University of Wisconsin–Madison
Resumen
El texto original del estudio, en el idioma en que se publicó.
Context
Whether ergocalciferol (D(2)) and cholecalciferol (D(3)) are equally effective to increase and maintain serum 25-hydroxyvitamin D [25(OH)D] concentration is controversial.
Objective
The aim of the study was to evaluate the effect of daily and once monthly dosing of D(2) or D(3) on circulating 25(OH)D and serum and urinary calcium.
Design, setting and participants
In a university clinical research setting, 64 community dwelling adults age 65+ were randomly assigned to receive daily (1,600 IU) or once-monthly (50,000 IU) D(2) or D(3) for 1 yr.
Main outcome measures
Serum 25(OH)D, serum calcium, and 24-h urinary calcium were measured at months 0, 1, 2, 3, 6, 9, and 12. Serum PTH, bone-specific alkaline phosphatase, and N-telopeptide were measured at months 0, 3, 6, and 12.
Results
Serum 25(OH)D was less than 30 ng/ml in 40% of subjects at baseline; after 12 months of vitamin D dosing, levels in 19% of subjects (n = 12, seven receiving daily doses and five monthly doses) remained low, despite compliance of more than 91%. D(2) dosing increased 25(OH)D(2) but produced a decline (P < 0.0001) in 25(OH)D(3). Substantial between-individual variation in 25(OH)D response was observed for both D(2) and D(3). The highest 25(OH)D observed was 72.5 ng/ml. Vitamin D administration did not alter serum calcium, PTH, bone-specific alkaline phosphatase, N-telopeptide, or 24-h urine calcium.
Conclusions
Overall, D(3) is slightly, but significantly, more effective than D(2) to increase serum 25(OH)D. One year of D(2) or D(3) dosing (1,600 IU daily or 50,000 IU monthly) does not produce toxicity, and 25(OH)D levels of less than 30 ng/ml persist in approximately 20% of individuals. Substantial between-individual response to administered vitamin D(2) or D(3) is observed.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.